Greiner D, Ochsendorf F R, Milbradt R
Zentrum der Dermatologie und Venerologie Abteilung II, J.W. Goethe-Universität, Frankfurt am Main.
Hautarzt. 1994 Jul;45(7):460-3. doi: 10.1007/s001050050104.
Since 1983 the administration of phenylalanine combined with UVA exposure (PAUVA) has been a well-known therapy for vitiligo. We have found no retrospective studies on this therapy. To document the long-term results and side effects, we performed a retrospective study on 41 patients who had received PAUVA therapy about 5 years ago. Examination was possible in 25 of the 41 patients, and 11 of them (44%) had permanent repigmentation. Depigmentation either during or after PAUVA therapy was recognized in 16 of the 25 patients (64%). In 52% of cases the patients were satisfied with the therapy and would repeat it; 68% would recommend it. Positive features in prognosis, i.e. indicative of good repigmentation, were vitiligo extending over less than 25% of the body surface, onset of vitiligo before the age of 21, generalized and symmetrical distribution and a long duration of UV therapy. None of our patients developed long-term side effects. PAUVA therapy is demonstrably a therapeutic alternative for certain patients.
自1983年以来，苯丙氨酸联合紫外线A照射（PAUVA）疗法一直是治疗白癜风的一种知名疗法。我们未发现关于该疗法的回顾性研究。为记录其长期疗效和副作用，我们对约5年前接受过PAUVA疗法的41例患者进行了一项回顾性研究。41例患者中有25例能够接受检查，其中11例（44%）有永久性色素再生。25例患者中有16例（64%）在PAUVA治疗期间或之后出现色素脱失。52%的患者对该疗法满意并愿意再次接受治疗；68%的患者会推荐该疗法。预后的积极特征，即表明色素再生良好的特征，包括白癜风累及体表面积小于25%、白癜风在21岁之前发病、广泛且对称分布以及紫外线治疗持续时间长。我们的患者均未出现长期副作用。PAUVA疗法显然是某些患者的一种治疗选择。
